This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
zacks-consensus-estimate: Archive
Fulgent Genetics, Inc. (FLGT) Q4 Earnings Top Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +433.33% and -2.39%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
FLGTNegative Net Change LUNGNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
1stdibs.com (DIBS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
1stdibs (DIBS) delivered earnings and revenue surprises of +25.00% and -0.59%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
DIBSNegative Net Change PDDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of +17.32% and +6.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ANIPNegative Net Change CRMDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Endeavour Silver (EXK) Misses Q4 Earnings Estimates
by Zacks Equity Research
Endeavour Silver (EXK) delivered earnings and revenue surprises of -33.33% and +18.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
EXKNegative Net Change ASMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Carter's (CRI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Carter's (CRI) delivered earnings and revenue surprises of +12.09% and +0.99%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
CRINegative Net Change CALNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
inTest Corporation (INTT) Q4 Earnings Match Estimates
by Zacks Equity Research
inTest (INTT) delivered earnings and revenue surprises of 0.00% and +3.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
INTTPositive Net Change TBCHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Docebo Inc. (DCBO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Docebo (DCBO) delivered earnings and revenue surprises of +36.36% and +0.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
DCBOPositive Net Change SURGNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BrightSpring Health Services, Inc. (BTSG) Q4 Earnings Lag Estimates
by Zacks Equity Research
BrightSpring Health Services, Inc. (BTSG) delivered earnings and revenue surprises of -1.49% and +5.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
BTSGPositive Net Change HQYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of +18.85% and -0.19%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
AMRXNegative Net Change ECORNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Northwest Natural (NWN) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Northwest Natural (NWN) delivered earnings and revenue surprises of +2.21% and -0.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
NWNPositive Net Change BLDPNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank